Propagermanium
- Generic Name
- Propagermanium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10Ge2O7
- CAS Number
- 12758-40-6
- Unique Ingredient Identifier
- 1Q2P9TO9Q7
- Associated Conditions
- -
- Associated Therapies
- -
Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 49
- Registration Number
- NCT05122182
- Locations
- ๐ฎ๐ณ
DM Wayanad Institute of Medical Sciences, Meppadi, India
๐ฎ๐ณSterling Hospital, Nigdi, India
๐ฎ๐ณJivanrekha Multi-Speciality Hospital, Pune, India
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT03649152
- Locations
- ๐ฆ๐บ
Westmead, Westmead, New South Wales, Australia
๐ฆ๐บRenal Research, Gosford, New South Wales, Australia
๐ฆ๐บBox Hill Hospital, Box Hill, Victoria, Australia
Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT03627715
- Locations
- ๐ฆ๐บ
Melbourne Renal Research Group, Melbourne, Victoria, Australia
๐ฆ๐บLiverpool Hospital, Liverpool, New South Wales, Australia
๐ฆ๐บRoyal North Shore Hospital, St Leonards, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath